Beleave Inc. (“Beleave” or the “Company“)
(CSE:BE) (OTCQX:BLEVF) is pleased to announce that it has entered into a
Brand Licensing Agreement with Kevin Smith and Jason Mewes, better
known as their onscreen characters, Jay and Silent Bob. Under the
agreement the Company, in partnership with Kevin Smith and Jason Mewes,
will be developing various proprietary strains geared towards the
recreational market which will be available under the Beleave Kannabis
brand.
“We are excited to welcome Kevin and
Jason to our team, their passion for the industry is something that
resonates with us,” commented Beleave CEO Andrew Wnek. “We look forward
to working together to explore unique, outside the box business
opportunities over the coming years.”
Kevin
Smith is a filmmaker, actor, comic book writer, author, and podcaster
well known for his comedy film Clerks (1994), which he wrote, directed,
co-produced, and acted in as the character Silent Bob. Jay and Silent
Bob have appeared in Smith’s follow-up films Mallrats, Chasing Amy,
Dogma, and Jay and Silent Bob Strike Back.
“It’s
no secret that I’m a fan of cannabis, it helps me sleep at night and
keeps my blood pressure down. I’ve seen cannabis drastically improve
the lives of some of the closest people in my life, and believe it could
be a viable alternative to the use of traditional pain killers,” said
Kevin Smith. “This culminating with the changing laws and perception
surrounding cannabis has me very excited to team up with Beleave, a
group I believe to be one of the most innovative in the Canadian
cannabis space.”
“It’s hard for me to argue
against the potential benefits that Medical Cannabis can bring. Much
like the Beleave team I have a personal connection to the remedy. Now
that Canada is on the verge of legalizing cannabis, I am looking forward
to the opportunity to work with the scientifically focused and forward
thinking team at Beleave, there’s no telling what we can dream up
together,” said Jason Mewes.
Jason Mewes, is
perhaps best known as the vocal half of the on-screen comedic duo, Jay
and Silent Bob. Mewes’ has reprised his role as celebrated character,
“Jay,” in a number of hit films. Mewes has captured audiences with
rebellious banter against his unspoken other half and long-time friend,
Kevin Smith (Silent Bob).
“Kevin and Jay played
the quintessential stoners in a bunch of 90’s comedies, but are serious
about the benefits of the cannabis lifestyle,” continued Beleave CEO
Andrew Wnek, “It’s definitely going to be fun watching them take an
active role in the space while developing strains together.”
About Beleave
Beleave
Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave
Kannabis Corp. (formerly First Access Medical Inc.) is a licensed
producer pursuant to the ACMPR. Beleave’s purpose-built facility is
located in Hamilton, Ontario.
For further information please contact:
Sebastian de Kloet
Phone: (905) 979 – 5173
Email: [email protected]
beleave.com
Forward-Looking Statements
This
news release contains “forward-looking information” within the meaning
of applicable securities law (“forward-looking statements”). The use of
any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”,
“may”, “will”, “project”, “should”, “believe” and other similar words,
or statements that certain events or conditions “may” or “will” occur
are intended to identify forward-looking information. These statements
are only predictions. Although the Company believes that the
expectations and assumptions on which the forward-looking information is
based are reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no assurance
that they will prove to be correct. These risks and uncertainties
include, but are not limited to, the Company’s ability to satisfy the
conditions associated with its cultivation license, the Company’s
ability to obtain a sales license and the related timing considerations,
the availability of further financing, consumer interest in its
products, competition, regulation, operational and technological risks,
and anticipated and unanticipated costs and delays. Since
forward-looking information addresses future events and conditions, by
its very nature it involves inherent risks and uncertainties. This
information speak only as of the date of this news release. Actual
results could differ materially from those currently anticipated due to a
number of factors and risks including various risk factors discussed in
the Company’s disclosure documents, which can be found under the
Company’s profile on www.sedar.com.
In the interest of full disclosure, we call the reader’s attention
to the fact that Equities.com, Inc. is compensated by the companies
profiled in the Spotlight Companies section. The purpose of these
profiles is to provide awareness of these companies to investors in the
micro, small-cap and growth equity community and should not in any way
be considered as a recommendation to buy, sell or hold these securities.
Equities.com is not a registered broker dealer, investment advisor,
financial analyst, investment banker or other investment professional.
We are a publisher of original and third party news and information. All
profiles are based on information that is available to the public. The
information contained herein should not be considered to be complete and
is not guaranteed by Equities.com to be free from misstatement or
errors. The views expressed are our own and not intended to be the basis
for any investment decision. Readers are reminded to do their own due
diligence when researching any companies mentioned on this website.
Always bear in mind that investing in early-stage companies is risky and
you are encouraged to only invest an amount that you can afford to lose
completely without any change in your lifestyle. Equities has been
compensated with cash, common shares and/or warrants for market
awareness services provided.
Read Next
